Press release
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018 by MarketResearchReports.biz
About B-Cell Chronic Lymphocytic Leukemia Market
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.
Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1581048
B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Request for TOC @ https://www.marketresearchreports.biz/reports/1581048/b-cell-chronic-lymphocytic-leukemia-pipeline-review-h1-2018-market-research-reports/toc
The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 11, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.
B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
B-Cell Chronic Lymphocytic Leukemia - Overview 8
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 27
AB Science SA 27
Aduro BioTech Inc 27
AstraZeneca Plc 28
Bayer AG 28
BioInvent International AB 29
Celgene Corp 29
Cell Source Inc 30
Cellectis SA 30
Chugai Pharmaceutical Co Ltd 30
Dynavax Technologies Corp 31
Elsalys Biotech SAS 31
iDD biotech SAS 32
Immunomedics Inc 32
Juno Therapeutics Inc 33
Lymphocyte Activation Technologies SA 33
MEI Pharma Inc 33
Millennium Pharmaceuticals Inc 34
Molecular Templates Inc 34
Novartis AG 35
Noxxon Pharma AG 35
Ono Pharmaceutical Co Ltd 35
Portola Pharmaceuticals Inc 36
Regeneron Pharmaceuticals Inc 36
Samumed LLC 37
Sunesis Pharmaceuticals Inc 37
TheraMAB LLC 38
Unum Therapeutics Inc 38
Xencor Inc 39
B-Cell Chronic Lymphocytic Leukemia - Drug Profiles 40
202-b - Drug Profile 40
2X-121 - Drug Profile 42
AB-8779 - Drug Profile 45
alemtuzumab biosimilar - Drug Profile 46
alisertib - Drug Profile 47
Aurixim - Drug Profile 53
AZD-4573 - Drug Profile 54
BI-1206 - Drug Profile 55
BION-1301 - Drug Profile 57
Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 59
Cellular Immunotherapy for Hematological Malignancies - Drug Profile 60
Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 61
Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile 64
Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 65
Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile 66
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 67
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 68
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 69
cerdulatinib - Drug Profile 70
copanlisib hydrochloride - Drug Profile 75
DTRMWXHS-12 - Drug Profile 82
ELB-021 - Drug Profile 83
IDD-001 - Drug Profile 84
IDD-002 - Drug Profile 85
lenalidomide - Drug Profile 86
ME-401 - Drug Profile 104
mRNA ACTR + rituximab - Drug Profile 106
MT-3724 - Drug Profile 108
olaptesed pegol - Drug Profile 111
REGN-1979 - Drug Profile 116
SD-101 - Drug Profile 117
SM-08502 - Drug Profile 122
TAB-08 - Drug Profile 123
tirabrutinib - Drug Profile 126
tisagenlecleucel - Drug Profile 129
tocilizumab - Drug Profile 140
UCART-22 - Drug Profile 151
UCARTCS-1 - Drug Profile 152
vecabrutinib - Drug Profile 153
XmAb-13676 - Drug Profile 156
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 158
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 160
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 161
Featured News & Press Releases 161
Appendix 163
Methodology 163
Coverage 163
Secondary Research 163
Primary Research 163
Expert Panel Validation 163
Contact Us 163
Disclaimer 164
Buy Now @ https://www.researchmoz.com/checkout?rep_id=1581048&licType=S
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018 by MarketResearchReports.biz here
News-ID: 955880 • Views: …
More Releases from MarketResearchReports.biz
Hydro-flyers Market: Moving Towards a Brighter Future
A hydro-flyer is an adventure sporting device which uses the propulsion of water jet technology to create continuous flight movement, where the lift and movement are controlled by the flyer. Hydro-flyers sporting devices make use of the flow of water power to drive the flyer to reach soaring heights. The rise in water sporting facilities is one of the major factors that promote the growth and demand for hydro-flyers in…
Outdoor Floodlights: Technology and Market Dynamics
Outdoor floodlights is a reliable, highly efficient, and economical solution for a wide range of outdoor applications. These lights are resistant to temperature fluctuations and they remain stable even in extreme climatic conditions. Unlike the traditional lights, floodlights remain stable and functional even in harsh climatic conditions. This makes them ideal for use in any climate and any outdoor application. Outdoor floodlights save a significant amount of energy and consume…
Snow Helmets Market Future Prospects and Regional Outlook
Riders are riding faster and getting bolder day by day. Hence, safety equipment need to be updated as per the requirement and changing time. Earlier, helmets were primarily used by extreme skiers and racers. They were used only on slopes. However, later, the use of helmets was made compulsory. Earlier, bulky black helmets were used by riders, which are outdated at present. Currently, new stylish helmets that can match with…
Predictions for 2019: Global Sparkling Water Dispensers Industry Is Set to Boom
Sparkling water dispensers are equipment used for dispensing carbonated water. These dispensers mix the still, filtered water with carbon dioxide before dispensing. Sparkling water dispensers are mostly used in households and commercial establishments such as amusement parks, hotels, restaurants, and sports arenas. A sparkling water dispenser has separate outlets for hot water and cold water. The hot water outlet does not require a separate filtration process. However, cold water is…
More Releases for Cell
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
Cell Banking Outsourcing Market Report 2018: Segmentation by Type of Bank (Maste …
Global Cell Banking Outsourcing market research report provides company profile for Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY…
